Ahn | 2012 | Double blind | South Korea | multicenter | 14 weeks | 46.68 | 40 | Mesoglow/IAL System | WSRS/GAIS/Complications |
Baumann | 2018 | Evaluator blind | USA | multicenter | 48 weeks | 53.7 | 162 | Restylane Defyne/Juvederm Ultra Plus | Complications |
Beer | 2007 | Evaluator blind | USA | single center | 6 months | 53±12 | 15 | HA/hylan B plus | WSRS/GAIS |
Brandt | 2010 | Double blind | USA | multicenter | 2 weeks | 53.4±8 | 60 | Perlane—LGP/Perlane –L—LGP with 0.3% lidocaine hydrochloride | Complications |
Buntrock | 2013 | Double blind | Germany | single center | 48 weeks | 52±5.6 | 20 | CPMHA/biphasic HA filler (NASHA) | WSRS |
Carruthers | 2005 | Double blind | Canada | multicenter | 12 months | 51,9 (34–83) | 150 | Restylane Perlane/Hylaform | Complications |
Choi | 2015 | Double blind | South Korea | multicenter | 24 weeks | 52.48 ± 8.23 | 66 | PP-501-A-Lidocaine/Restylane Lidocaine | WSRS/GAIS/Complications |
Dover | 2009 | Double blind | USA | multicenter | 24 weeks | 54.05 | 283 | NASHA | Complications |
Fagien | 2018 | Evaluator blind | USA | multicenter | 48 weeks | 53.9±8.22 | 170 | Juvederm Ultra/Restylane Refyne with lidocaine 3% | Complications |
Fino | 2019 | Double blind | Italy | single center | 6 months | 50.4±8.3 | 65 | Ial System Duo/Belotero Basic/Balance | Complications |
Galadari | 2015 | Double blind | United Arab Emirates | single center | 12 months | 46 | 40 | polycaprolactone (PCL)/NASHA | WSRS |
Gold | 2018 | Double blind | USA | multicenter | 24 weeks | 55.4±10.1 | 163 | Revanesse Versa/Restylane | Complications |
Grimes | 2009 | Double blind | USA | multicenter | 25 weeks | 50 (32–75) | 53 | Juvederm Ultra, Juvederm Ultra Plus, Juvederm 30, Hylaform, Hylaform Plus, Captique | Complications |
Heden | 2010 | Double blind | Sweden | multicenter | 12 months | 54 | 42 | NASHA | Complications |
Hong | 2018 | Patient/evaluator-blinded | South Korea | single center | 48 weeks | 48.3±7.36 | 91 | DHF-001, Restylane SubQ | WSRS/ |
Hu | 2017 | Evaluator blind | China | single center | 12 months | (30–65) | 57 | HA (Nature, Beijing Aimeike Bio-tech Co.), autologous fat injection | WSRS/GAIS/Complications |
Hyun | 2014 | Evaluator blind | South Korea | multicenter | 24 weeks | 51.9±6.9 | 58 | Restylane, Aesthefill | WSRS/Complications |
Joo | 2016 | Double blind | South Korea | multicenter | 24 weeks | 47.62±7.64 | 60 | Neuramis, Perlane-L | WSRS/GAIS |
Kim | 2016 | Evaluator blind | South Korea | multicenter | 24 months | 49.6±11.8 | 13 | HA-G-monophasic, HA-P-biphasic | GAIS/Complications |
Lee | 2014 | Double blind | South Korea | multicenter | 12 months | 42.2 | 57 | Terafill, Koken | WSRS/GAIS |
Levy | 2009 | Single blind | Switzerland | multicenter | | 53 | 126 | Juvederm Ultra 3, Restylane Perlane | Complications |
Lindqvist | 2005 | Single blind | Sweden/Norway | multicenter | 12 months | 49.4 | 68 | Perlane, Zyplast | Complications |
Lupo | 2007 | Double blind | USA | multicenter | 24 weeks | 49 | 87 | Juvederm Ultra +, Zyplast | WSRS |
Marmur | 2010 | Single blind | USA | single center | 1 month | | 50 | CaHA+lidocaine, CaHA | Complications |
Moers-Carpi | 2007 | Evaluator blind | Germany/Spain | multicenter | 12 months | 50.5 (34–67) | 60 | CaHA, NASHA | Complications |
Monheit | 2018 | Double blind | USA | multicenter | 6 months | 54 (33–83) | 123 | VYC-17.5L (HA+lidocaine) | Complications |
Monheit | 2010 | Patient/evaluator-blinded | USA | multicenter | 36 weeks | 52.7±9.3 | 140 | DGE, NASHA | Complications |
Monheit | 2010 | Single blind | USA | single center | 2 weeks | 45 (29–68) | 45 | Prevelle SILK, Captique | Complications |
Moon | 2014 | Evaluator blind | South Korea | multicenter | 6 months | 47.2 (21–66) | 57 | Porcine collagen, Bovine collagen | WSRS/Complications |
Narins | 2007 | Evaluator blind | USA | multicenter | 6 months | 56 | 149 | Dermicol-P35, NASHA | Complications |
Narins | 2010 | Evaluator blind | USA | multicenter | 24 weeks | 52.4 (25.7–75.7) | 118 | CPMHA. bovine collagen | GAIS |
Nast | 2011 | Double blind | Germany | single center | 4 weeks | 54.8±8.8 | 60 | HA-biphasic, HA-monophasic | WSRS |
Onesti | 2009 | Double blind | Italy | single center | 6 months | 50.2 | 74 | Captique, Puragen | Complications |
Pak | 2015 | Double blind | South Korea | multicenter | 6 months | | 69 | Neuraminis, Restylane | WSRS/Complications |
Park | 2011 | Evaluator blind | South Korea | single center | 4 months | 48.4±5 | 12 | Teosyal, HA (Titan) + Infrared | WSRS/GAIS/Complications |
Park | 2015 | Double blind | South Korea | multicenter | 6 months | 45.76±7.77 | 98 | PP-501-B, Restylane Perlane PER | WSRS/GAIS/Complications |
Prager | 2010 | Patient/evaluator-blinded | Germany | single center | 1 month | 45.8 | 20 | Belotero, Restylane | Complications |
Prager | 2012 | Patient/evaluator-blinded | Germany | single center | 12 months | 45.8 | 20 | Belotero, Restylane | Complications |
Rhee | 2014 | Evaluator blind | South Korea | multicenter | 6 months | | 68 | Elravie, Restylane | WSRS |
Rzany | 2011 | Evaluator blind | France/Germany | multicenter | 6 months | 50.6±10.1 | 81 | Emervel Classic, Restylane | Complications |
Rzany | 2017 | Patient/evaluator-blinded | France/Germany | multicenter | 18 months | 50.8 | 81 | Emervel Classic, Restylane | Complications |
Schachter | 2016 | Double blind | Canada | multicenter | 1 month | 48.84±9.43 | 102 | CaHA (Radiesse) + lidocaine, CaHA (Radiesse) | Complications |
Sharma | 2011 | No blinding | UK | single center | 9 months | | 17 | Juvederm Ultra 3, Uma Jeunesse | Complications |
Sharma | 2018 | Single blind | UK | single center | 9 months | 40.5±11.02 | 73 | Uma Jeunesse Classic, Uma Jeunesse Ultra | Complications |
Smith | 2007 | Evaluator blind | USA | multicenter | 6 months | 54.7 | 117 | CaHA (Radiesse), human-based collagen (Cosmoplast) | Complications |
Suh | 2017 | Double blind | South Korea | multicenter | 24 weeks | 46.02±7.21 | 60 | Dermalax implant plus, Restylane Sub-Q | Complications |
Taylor | 2010 | Patient/evaluator-blinded | USA | multicenter | 24 weeks | | 150 | Restylane, Perlane | WSRS/GAIS |
Weiss | 2010 | Double blind | USA | multicenter | 2 weeks | 52.1±6.6 | 60 | Restylane + lidocaine, Restylane | Complications |
Wu | 2016 | Double blind | China | multicenter | 15 months | 44.7 (24–61) | 88 | Restylane, BioHyalux | Complications |
Wu | 2016 | Double blind | China | multicenter | 6 months | 39 (26–58) | 109 | Restylane, Juvederm Ultra | Complications |
Zhou | 2016 | Double blind | China | single center | 24 weeks | 47.85 | 50 | Matrifill, Restylane | WSRS |